ABP 215 and bevacizumab in NSCLC patients: time course and magnitude of response in the phase 3 comparative trial (MAPLE)
Citation
Thatcher N, Goldschmidt J, Thomas M, Schenker M, Pan Z, Hanes V. P2.13-40ABP 215 and bevacizumab in NSCLC patients: time course and magnitude of response in the phase 3 comparative trial (MAPLE). J Thorac Oncol. 2018 Oct;13(10):S814.Journal
Journal of Thoracic OncologyDOI
10.1016/j.jtho.2018.08.1435Additional Links
https://dx.doi.org/10.1016/j.jtho.2018.08.1435Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.jtho.2018.08.1435